Inside informationEnglish
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Inventiva
- Filed
- 20/02/2025, 22:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 119648_20250220